Search

everythinglearnresearchcommunity

for

Search:↓

Intralesional methotrexate and triamcinolone acetonide are more effective than Vitamin D3 for treating alopecia areata.

Formestane is a preferred second-line treatment for advanced breast cancer in postmenopausal women because it's effective and has fewer side effects.

Baricitinib is effective and safe for treating severe alopecia areata.

Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.

A bull with a gene mutation was asymptomatic, synthetic retinoids cause hair loss, and new therapeutic targets were identified for skin diseases.

Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.

Ritlecitinib can help about 14,000 people with severe hair loss.

Etanercept may not prevent alopecia areata from coming back.

Thymosin β4 helps improve skin healing and reduce scarring.

A new lotion with halobetasol and tazarotene successfully treats acne keloidalis nuchae.

Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.

Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.

Tofacitinib can be effective in treating hair loss caused by alopecia areata.

Cyclosporine showed some improvement in alopecia areata but results were not statistically significant.

Ritlecitinib 50 mg effectively promotes and sustains hair regrowth in alopecia areata patients.

Methotrexate with corticosteroids can help regrow hair in severe alopecia areata but may cause relapses and side effects.

Ritlecitinib is generally safe for alopecia areata patients over 72 months.

Amotosalen-treated donor T-cells can prevent late CMV infection after bone marrow transplants.

Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.

Bicalutamide, a drug with a good safety profile, is a promising new treatment for female pattern hair loss.

JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.

New butyric acid prodrugs show promise for cancer treatment, anemia management, and protecting hair from chemotherapy damage.

Systemic steroids temporarily improve severe alopecia areata in children but often lead to relapse.

Patients with certain baseline characteristics are more likely to benefit early from baricitinib for alopecia areata.

The new compound was more effective than finasteride in reducing markers of hair loss and prostate issues in cell tests.

A patient's grey hair regained color during treatment with adalimumab.

Baricitinib improved platelet counts and alopecia in a 16-year-old with chronic immune thrombocytopenia.

Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.

Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.